Objective: In an effort to account for deficiencies in axonal transport that limit the effectiveness of neurotrophic factors, this study tested the safety and feasibility, in moderately advanced Parkinson disease (PD), of bilaterally administering the gene therapy vector AAV2-neurturin (CERE-120) to the putamen plus substantia nigra (SN, a relatively small structure deep within the midbrain, in proximity to critical neuronal and vascular structures).
Abundant preclinical research argues that neurotrophic factors offer promising therapies for Parkinson disease (PD). 1 Clinical trials have generally been disappointing, likely because of difficulties delivering sustained bioactive protein throughout the targeted brain region. Gene transfer can potentially solve these problems. 1 A double-blind study testing putaminal gene delivery of the neurotrophic factor neurturin (NRTN) failed to meet its primary endpoint at 12 months but showed benefit for the predefined primary endpoint at 18 months and for several secondary endpoints at 12 and 18 months (no measure similarly favored sham). 1,2 Postmortem studies suggest that serious deficiencies in axonal transport in PD limited NRTN transport to the substantia nigra pars compacta (SNc), thereby impairing the ability of putaminal delivery to activate repair genes in SNc neurons, thereby reducing and delaying clinical benefit. 3 We therefore initiated a study testing NRTN gene delivery to both SNc and putamen. However, a number of safety concerns have been raised regarding stereotactically targeting the SNc and expressing neurotrophic factors in the substantia nigra (SN) and surrounding structures. [4] [5] [6] Based on safety associated with targeting the SNc and neighboring regions in patients with PD with deep brain stimulation 7 and fetal tissue transplant, 8 and the lack of serious side effects observed following NRTN gene delivery to the SNc in preclinical studies, 9 we began a clinical trial in patients with advanced PD. In the present article, we present the 24-month results of an open-label safety study of 6 patients who underwent bilateral NRTN gene delivery (CERE-120) to the putamen and SNc.
METHODS Standard protocol approvals, registrations, and patient consents. This study is registered with ClinicalTrials.gov, number NCT00985517, was approved by the US Food and Drug Administration, and was publicly discussed and reviewed by the Recombinant DNA Advisory Committee of the NIH. The study protocol and patient consent forms were approved by institutional ethics and biological safety committees at each institution. Each patient signed informed consent before entry into the trial.
Subjects. Inclusion/exclusion criteria were similar to prior AAV2-NRTN clinical trials, involving subjects diagnosed with idiopathic PD according to UK Brain Bank criteria. 2, 10 Dosing and assessment. To assess the feasibility and safety of targeting the SN plus putamen with AAV2-NRTN in PD, 2 dose cohorts were tested (3 subjects each) with a 1-month interval between each surgery and a 5-week hiatus between the low-dose and high-dose cohorts. An independent data monitoring committee (DMC) reviewed the entire CERE-120 safety profile after each surgery. In the first cohort, patients received a total dose of CERE-120 of 4.0 3 10 11 vector genomes (vg) to the SN, and 5.4 310 11 vg to the putamen (the same putaminal dose used in the prior phase IIa CERE-120 trial). 2 The SN dose was determined based on betweenspecies "dose scaling," designed to adequately cover the SN without risk of substantial spread to non-SN structures. 9 The second dose cohort received the same dose to the SN and a nearly 4-fold higher dose to the putamen, for a total dose of 24.0 3 10 11 vg, in a volume of 360 mL. The infusion rate was increased from 2 mL/min to 3 mL/min for the putamen (but remained 2 mL/min for the SN), using an automated infusion pump (World Precision Instruments, Sarasota, FL).
Following surgery, subjects were evaluated for safety and tolerability at week 2, month 1, month 3, and every 3 months thereafter for the next 2 years, as well as on number of motor and quality-of-life measurements assessed at baseline and at visits starting at month 6. This design, wherein each subject served as his or her own control (and comparisons in performance were made on protocol-prescribed, objective measures between pretreatment baseline scores and a series of post-treatment scores), was intended to provide Class IV evidence regarding the feasibility and safety of administering CERE-120 to the SN and putamen in patients with moderately advanced PD.
Stereotactic targeting and surgery. Targeting and stereotactic surgery were performed in a similar manner to past gene transfer of NRTN studies for PD. 2, 10 All subjects were administered CERE-120 bilaterally, using a single burr hole per hemisphere. To help ensure uniformity of dosing across subjects and clinical sites, and to reduce the risk of mistargeted protein, a consensus with respect to targets and trajectories was required between the operating neurosurgeon and an independent neurosurgical reviewer.
Two CERE-120 bolus infusions were delivered to the SN via one trajectory in each hemisphere; doses were separated by 2-4 mm (figure). CERE-120 was then delivered to the putamen via 3 trajectories per hemisphere. The 3 putaminal target sites were evenly spaced across the anterior-posterior extent of the putamen. If an extremely narrow area at the posterior end of the putamen occurred, this "tail" was excluded for purposes of selecting target locations. In each subject, 2 of the 3 target locations were positioned posterior to the anterior commissure. All 3 targets were positioned in the ventral half of the putamen, approximately twothirds of the way down from the dorsalmost edge, but at least 4 mm from the inferior boundary, and all were relatively centered in the medial-lateral dimension.
Postsurgical MRIs were reviewed by a central neuroradiologist (Daniel Lefton, Beth Israel Medical Center, New York, NY) to confirm adherence to targeting guidelines and to identify any safety issues. In many instances a clear signal from the needle track could be seen on the postsurgical MRI confirming appropriate trajectories to the putamen or SN, though it was never possible to identify with certainty the location of the tip of the injection cannula. In no case was any evidence for any mistargeted trajectories observed, nor did any individual differences in size or shape of putamen negatively impact the ability to target it.
RESULTS
Six subjects underwent the procedure and were followed for 2 years. Demographic information is provided in table 1. No serious adverse events (SAEs) were reported. The most common adverse events were incision site pain (n 5 4), dyskinesias (n 5 4), headache (n 5 4), and abnormal dreams (n 5 4); these were transient, considered clinically insignificant, and unrelated to AAV2-NRTN treatment. Dyskinesias reported in this study were not increased in severity, occurred no more frequently than in the earlier putaminal-only phase I CERE-120 study, and were all transient. 10 No patient experienced off-medication dyskinesia. No clinically significant changes were detected on physical or neurologic examination or vital signs. Specifically, there was no clinically significant weight loss associated with the procedure ( Parkinson's Disease Questionnaire-39: Activities of Daily Living scores appeared stable (25 6 2.6 and 25 6 6.1 at baseline and 24 months, respectively). DISCUSSION We report here the long-term (2-year) safety results from 6 subjects with PD who were treated with AAV2-NRTN (a gene-transfer viral vector encoding the neurotrophic factor NRTN) delivered to both the SNc and putamen. In this phase I study, CERE-120 delivered into both the SNc and putamen was well-tolerated, with no safety or serum laboratory complications identified over the course of 2 years of follow-up. No SAEs were reported in any subject; all adverse events were expected for an advanced PD patient population undergoing a neurosurgical procedure, and none was clinically significant or enduring. Specifically, no problems were encountered with respect to stereotactically targeting the SNc, expression of a trophic factor in the SNc, or possible spread to adjacent sites like the ventral tegmental area or hypothalamus. More specifically, we did not observe weight loss, which has been reported as a potential concern for targeting the SN with neurotrophic factors, based on certain preclinical studies, 5,6,11 though others suggested that outcome is likely due to mistargeting protein extending into the ventricles or hypothalamus. 9 We also did not observe any evidence of psychiatric symptoms such as addiction or psychosis that theoretically might result from trophic enhancement of the ventral tegmental area. 4 Thus, these data provide support for the feasibility and safety of targeting both the SN and putamen with AAV2-NRTN in subjects with moderately advanced PD. This open-label study was designed to generate preliminary safety and tolerability information. Based on the data generated in this study, a multicenter, doubleblind, sham surgery-controlled trial has been launched to assess the effect of combined intraputaminal and SNc gene delivery of NRTN on key motor and quality-of-life measurements in 51 patients with moderately advanced PD. Consistent with the 2-year safety results reported here, no serious, unexpected safety issues have been encountered after more than a year of follow-up after dosing in any of the subjects in this ongoing phase IIb study. 12 
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